<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Toxic Dolls | Larsen Marshall | Activity</title>
	<link>https://toxicdolls.com/members/cancloud5/activity/</link>
	<atom:link href="https://toxicdolls.com/members/cancloud5/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Larsen Marshall.</description>
	<lastBuildDate>Thu, 14 May 2026 22:11:49 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">30834110c45370017fd8fd1dd2b7037d</guid>
				<title>Larsen Marshall posted an update: Tumor cells that were detectable in urine patient samples [&#133;]</title>
				<link>https://toxicdolls.com/activity-2/p/13672/</link>
				<pubDate>Sat, 28 Jun 2025 12:27:25 +0000</pubDate>

									<content:encoded><![CDATA[<p>Tumor cells that were detectable in urine patient samples disappeared after catumaxomab therapy. Endoscopically confirmed recurrence-free intervals were 32 and 25 months. Our data suggest that intravesical administration of catumaxomab in NMIBC is feasible, safe and efficacious, thus arguing for further clinical development of catumaxomab in this&hellip;<span class="activity-read-more" id="activity-read-more-13672"><a href="https://toxicdolls.com/activity-2/p/13672/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">5a595f17da8f7dd410b8cec2ed9acbe7</guid>
				<title>Larsen Marshall posted an update: Increasing mNUTRIC was independently associated with 60-day [&#133;]</title>
				<link>https://toxicdolls.com/activity-2/p/10252/</link>
				<pubDate>Tue, 24 Jun 2025 12:53:02 +0000</pubDate>

									<content:encoded><![CDATA[<p>Increasing mNUTRIC was independently associated with 60-day mortality, whereas increasing SARC-CALF and CFS showed a strong trend towards a higher 60-day mortality. Discriminative ability of NUTRIC-SF for 60-day mortality is better than its component (C-statistics, 0.722; 95% confidence interval [CI], 0.677-0.868). Every increment of 300 kcal/day&hellip;<span class="activity-read-more" id="activity-read-more-10252"><a href="https://toxicdolls.com/activity-2/p/10252/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">77482a7053767e612d77521564666b05</guid>
				<title>Larsen Marshall posted an update: Despite the increasing prevalence and costs of breast cancer [&#133;]</title>
				<link>https://toxicdolls.com/activity-2/p/8348/</link>
				<pubDate>Mon, 23 Jun 2025 11:43:40 +0000</pubDate>

									<content:encoded><![CDATA[<p>Despite the increasing prevalence and costs of breast cancer (BC), little is known about its adverse event (AE)-related costs in Asia. This study aimed to estimate the healthcare expenditures of AEs in patients with BC in Taiwan.</p>
<p> This is a retrospective claims database analysis. The medical costs associated with BC AEs during the&hellip;<span class="activity-read-more" id="activity-read-more-8348"><a href="https://toxicdolls.com/activity-2/p/8348/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">92e71916d438b9aadc35e7ca0cfc4d24</guid>
				<title>Larsen Marshall became a registered member</title>
				<link>https://toxicdolls.com/activity-2/p/8299/</link>
				<pubDate>Mon, 23 Jun 2025 11:07:26 +0000</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>